What Are MicroRNAs?

MicroRNAs (miRNAs) are short, non-coding RNA molecules, typically 21–23 nucleotides in length, that function as post-transcriptional regulators of gene expression. They are transcribed by RNA polymerase II as primary miRNAs (pri-miRNAs), which are then processed in the nucleus by the Drosha-DGCR8 complex into precursor miRNAs (pre-miRNAs). After export to the cytoplasm via Exportin-5, the Dicer enzyme cleaves them into mature miRNA duplexes. One strand of the duplex, the guide strand, is loaded into the RNA-induced silencing complex (RISC). Within RISC, the miRNA binds to complementary sequences in the 3’ untranslated region (UTR) of target messenger RNAs (mRNAs), leading to translational repression or mRNA destabilization and degradation.

Through this mechanism, a single miRNA can regulate hundreds of target genes, forming complex regulatory networks. The specificity of miRNA–mRNA binding is primarily determined by the seed region (nucleotides 2–8 at the 5’ end of the mature miRNA). This ability to fine-tune gene expression makes miRNAs critical players in development, cell differentiation, and metabolic homeostasis. Over 2,600 mature miRNAs have been identified in humans, and many are conserved across species, underscoring their fundamental biological roles. For a comprehensive overview of miRNA biogenesis and function, see this review on miRNA mechanisms.

MicroRNA Dysregulation in Obesity

Obesity is characterized by excessive adipose tissue accumulation resulting from an imbalance between energy intake and expenditure. Adipose tissue is not merely a passive energy reservoir but an active endocrine organ that secretes adipokines, cytokines, and other signaling molecules. In obesity, adipocyte hyperplasia and hypertrophy are accompanied by chronic low-grade inflammation, altered lipid metabolism, and insulin resistance. MicroRNAs are intimately involved in these processes, with numerous miRNAs showing perturbed expression in adipose tissue, blood, and other metabolic organs of obese individuals.

miRNAs Promoting Adipogenesis and Fat Accumulation

Several miRNAs act as pro-adipogenic factors. miR-143 is one of the most studied. It promotes adipocyte differentiation by targeting MAPK7 and other genes, thereby enhancing the expression of transcription factors such as PPARγ and C/EBPα. Overexpression of miR-143 in preadipocytes accelerates their conversion into mature adipocytes, and its levels are elevated in both subcutaneous and visceral adipose tissue from obese patients. Similarly, the miR-17-92 cluster (including miR-17, miR-20a, and miR-92a) positively regulates adipogenesis by inhibiting the tumor suppressor Rb2/p130, which normally suppresses PPARγ expression.

Another pro-obesogenic miRNA is miR-21. It targets PTEN, a negative regulator of the PI3K/Akt pathway, thereby promoting adipogenesis and inhibiting lipolysis. In addition, miR-132 has been shown to enhance adipogenesis by targeting SIRT1 and promoting the expression of PPARγ. Elevated levels of these miRNAs in obesity correlate with increased fat mass and body mass index (BMI). There is also growing evidence that miR-26b plays a role in adipogenesis by targeting ADAM17 and regulating the Notch signaling pathway, which in turn influences preadipocyte commitment and differentiation.

miRNAs Regulating Lipid Metabolism and Energy Expenditure

Beyond adipogenesis, miRNAs control lipid storage and oxidation. miR-33 is encoded within introns of the SREBF2 gene and plays a central role in cholesterol and fatty acid homeostasis. It represses the expression of several genes involved in cholesterol efflux (e.g., ABCA1, ABCG1), fatty acid β-oxidation (e.g., CPT1A, PRKAA1), and insulin signaling (e.g., IRS2). In the liver, overexpression of miR-33 reduces HDL cholesterol and increases hepatic lipid content, promoting steatosis. In adipose tissue, miR-33 impairs mitochondrial function and browning of white adipose tissue, reducing energy expenditure.

miR-155 is another miRNA with important metabolic functions. It is downregulated in adipose tissue of obese mice and humans. Restoration of miR-155 in adipocytes enhances the expression of thermogenic genes such as UCP1 and PGC1α, promoting beige adipocyte formation and increasing energy expenditure. Conversely, miR-155 deficiency leads to obesity and insulin resistance when mice are fed a high-fat diet. Additionally, miR-27a is a negative regulator of adipogenesis and lipid accumulation. It targets PPARγ and C/EBPα, and its expression is reduced in obesity, allowing unchecked adipocyte differentiation. Understanding these opposing actions of different miRNAs is key to developing targeted interventions.

Inflammatory miRNAs in Obese Adipose Tissue

Obesity-associated inflammation is partly driven by pro-inflammatory miRNAs. miR-146a and miR-155 are upregulated in adipose tissue macrophages of obese individuals, where they modulate the production of inflammatory cytokines such as TNF-α and IL-6. While miR-146a exerts an anti-inflammatory feedback loop by targeting IRAK1 and TRAF6, excessive miR-155 can exacerbate inflammation. The balance of these miRNAs influences the macrophage polarization state (M1 vs. M2) and overall adipose tissue inflammation. miR-223 is another miRNA enriched in macrophages that helps control inflammation by targeting NLRP3 inflammasome components; its dysregulation in obesity contributes to sustained inflammatory signaling. For further reading on miRNA dysregulation in obesity, refer to this comprehensive review on miRNAs in obesity.

MicroRNA in Type 2 Diabetes

Type 2 diabetes (T2D) is characterized by insulin resistance in peripheral tissues and progressive β-cell dysfunction leading to hyperglycemia. Extensive evidence implicates miRNAs in both the initiation and progression of T2D. Numerous circulating miRNAs serve as biomarkers for early detection and risk stratification. Moreover, intracellular miRNAs in the liver, muscle, adipose tissue, and pancreatic islets directly modulate insulin signaling, glucose uptake, and insulin secretion.

miRNAs Affecting Insulin Sensitivity

In the liver, miR-29a/b/c family members are elevated in obese, insulin-resistant conditions. They target IRS1, AKT2, and PPARGC1A (PGC1α), thereby attenuating insulin signaling and promoting gluconeogenesis. Knockdown of miR-29 improves insulin sensitivity and reduces glucose production in hepatocytes. Similarly, miR-103 and miR-107 are upregulated in the liver of obese mice. These miRNAs target CAV1 (caveolin-1), a scaffold protein essential for insulin receptor stability and signaling. Inhibition of miR-103/107 using antisense oligonucleotides enhances caveolin-1 expression, restores insulin receptor levels, and improves glucose homeostasis. This strategy has shown promising results in rodent models of diet-induced obesity.

In adipose tissue, miR-143 and miR-145 contribute to insulin resistance by targeting AKT1 and IRS4, respectively. Elevated levels of these miRNAs in visceral fat correlate with reduced Akt phosphorylation and impaired GLUT4 translocation. In skeletal muscle, miR-133b is downregulated in diabetic patients, and its overexpression improves glucose uptake via GLUT4 upregulation. miR-181a is another miRNA that modulates insulin sensitivity; it is upregulated in insulin-resistant muscle and targets SIRT1, leading to reduced mitochondrial function and glucose metabolism. These findings highlight the tissue-specific and sometimes opposing roles of miRNAs in insulin action.

miRNAs and Pancreatic β-Cell Function

β-cell dysfunction is a hallmark of T2D progression. MicroRNAs are essential for β-cell development, proliferation, and insulin secretion. miR-375 is one of the most abundant miRNAs in pancreatic islets. It is required for normal β-cell mass and function. Targeted deletion of miR-375 in mice leads to reduced β-cell proliferation and impaired glucose-stimulated insulin secretion. Conversely, overexpression of miR-375 protects β-cells from apoptosis induced by lipotoxicity and ER stress, partly through targeting PDK1 and JAK2. miR-7 is also highly expressed in β-cells and inhibits cell proliferation by targeting the mTOR pathway. Interestingly, miR-7 is upregulated in islets from T2D donors, suggesting its role in the failure of compensatory β-cell expansion.

Other key miRNAs include miR-200 family members, which are induced by hyperglycemia and oxidative stress. They promote β-cell apoptosis by repressing Bcl2 and activating the p53 pathway. miR-30d and miR-124a modulate insulin secretion by targeting ROCK1 and FOXA2, respectively. Additionally, miR-204 has been shown to inhibit insulin secretion by targeting Insulin 1 and 2 genes, and its levels are elevated in diabetic islets. These miRNAs offer potential biomarkers for β-cell health and targets for preserving insulin secretion. For detailed insights, see this review on miRNAs in β-cell function.

Circulating miRNAs as Biomarkers for T2D

Circulating miRNAs are stable in blood and can be measured non-invasively, making them attractive as diagnostic and prognostic biomarkers. Specific miRNA signatures have been identified in T2D patients. For instance, reduced levels of miR-126 in plasma have been associated with impaired angiogenic responses and increased risk of diabetes complications. Elevated miR-29a and miR-133b in serum correlate with insulin resistance and glycemic status. Panels of miRNAs, such as those including miR-15a, miR-223, and miR-28-3p, show promise for distinguishing prediabetes from overt T2D. Large-scale validation studies are underway to translate these findings into clinical tools.

Therapeutic Potential and Challenges of Targeting miRNAs

The ability of miRNAs to simultaneously regulate multiple gene targets makes them attractive for therapeutic intervention. Two main strategies exist: inhibiting disease-associated miRNAs using antagomirs or miRNA sponges, and restoring protective miRNAs using synthetic miRNA mimics. Several miRNA-targeting drugs have entered clinical trials for other diseases, and metabolic applications are under active investigation.

Antagomir Approaches in Preclinical Models

As mentioned, inhibition of miR-103/107 with antisense oligonucleotides improves insulin sensitivity and lowers blood glucose in diabetic mice. Subcutaneous delivery of these inhibitors results in widespread uptake by the liver and adipose tissue. Targeting miR-33 using antagomirs increases ABCA1 expression and raises HDL cholesterol while reducing atherosclerosis in mice. However, long-term inhibition of miR-33 also led to increased hepatic steatosis in some studies, highlighting the need for careful dosing and monitoring. miR-21 inhibition reduces adipogenesis and improves insulin sensitivity in high-fat diet-fed mice. Another emerging target is miR-34a, which is upregulated in the liver of obese mice and contributes to steatosis and insulin resistance; antagomir treatment reduces fat accumulation and improves glucose metabolism. These proof-of-concept studies demonstrate the feasibility of miRNA-based therapy for obesity and diabetes.

miRNA Mimics for Restoration

In cases where protective miRNAs are downregulated, synthetic mimics can restore their levels. For instance, systemic administration of miR-155 mimics using lipid nanoparticles increased energy expenditure and reduced obesity in mice. Similarly, delivery of miR-26a mimics has been shown to suppress lipogenesis and improve insulin sensitivity in the liver. However, context matters: for example, delivering miR-143 inhibitors (rather than mimics) may be needed depending on the tissue and disease stage. Challenges include ensuring that mimics are loaded into the RISC complex without triggering off-target effects or activating the innate immune system. Chemical modifications such as 2′-O-methyl and locked nucleic acid (LNA) are used to enhance stability. Advances in nanoparticle formulations and GalNAc conjugates are improving delivery to specific tissues like the liver.

Delivery Challenges and Safety

The main hurdles for miRNA therapeutics include nuclease degradation, renal clearance, poor cellular uptake, and off-target effects. Chemical modifications such as 2’-O-methylation, phosphorothioate backbone, and locked nucleic acid (LNA) nucleotides improve stability and binding affinity. Conjugation to N-acetylgalactosamine (GalNAc) enhances liver-specific delivery and has been successful for siRNA drugs like inclisiran. For miRNA therapeutics, lipid nanoparticles and viral vectors (e.g., adeno-associated virus) are also being explored. Safety remains a critical concern because miRNAs regulate many genes; unintended targeting could lead to toxicity. Long-term animal studies evaluate potential side effects, including immunosuppression or tumorigenesis. A detailed discussion of miRNA therapeutics is available in this Nature Reviews Drug Discovery article.

Future Directions and Clinical Perspectives

The field of miRNA regulation in metabolic disease is advancing rapidly. Several key areas warrant further investigation. First, the role of extracellular miRNAs (e.g., exosomal miRNAs) in inter-organ communication is emerging. Adipose-derived exosomes containing miR-155, miR-27a, or miR-222 can travel to the liver, muscle, or pancreatic islets, modulating insulin sensitivity and β-cell function. Targeting these exosomal microRNAs could block pathological signaling between tissues.

Second, single-cell and spatial transcriptomics are revealing cell-type-specific miRNA expression in adipose and islet tissues, offering higher-resolution targets. For example, miRNAs expressed specifically in adipose tissue macrophages versus adipocytes may be targeted more precisely. Third, combinatorial therapies that simultaneously modulate multiple miRNAs (e.g., using a single polycistronic antagomir) may achieve synergistic benefits. Fourth, unbiased screening methods, such as CRISPR-Cas9 screens to identify miRNA targets, continue to uncover novel regulatory networks. Finally, the identification of circulating miRNA signatures as non-invasive biomarkers for early diagnosis and progression monitoring of obesity and T2D is progressing. Large-scale longitudinal studies will validate these biomarkers.

Additionally, the development of tissue-specific miRNA delivery systems, such as peptide-conjugated nanoparticles or engineered exosomes, holds promise for reducing off-target effects. Personalized miRNA therapy based on an individual’s miRNA expression profile and genetic background is another horizon. As our understanding of miRNA biology deepens and as new technologies emerge, microRNAs will likely become integral components of future precision medicine approaches for obesity, diabetes, and their associated complications.

Conclusion

MicroRNAs are fundamental regulators of the complex molecular networks underlying obesity and type 2 diabetes. They influence adipogenesis, lipid metabolism, inflammatory responses, insulin signaling, and β-cell survival and function. Dysregulation of specific miRNAs contributes to the pathogenesis of these metabolic disorders, and preclinical studies have shown that manipulating miRNA levels can improve metabolic outcomes. Despite challenges in delivery, stability, and safety, the development of miRNA-based therapeutics remains a promising frontier. As our understanding of miRNA biology deepens and as new technologies for tissue-specific targeting emerge, microRNAs will likely become integral components of future precision medicine approaches for obesity, diabetes, and their associated complications.